What antibodies are associated with dermatomyositis?

Answer generated by Itaca · 5 sources · July 29, 2025

Original question

dermatomyositis antibodies

Summary

Dermatomyositis (DM) is associated with several myositis-specific autoantibodies (MSAs) that help in diagnosis, classification, and prognosis. The main antibodies linked to DM include anti-Mi-2, anti-MDA5, anti-TIF1γ, anti-NXP-2, and anti-SAE. Each antibody correlates with distinct clinical features, such as cancer association, interstitial lung disease (ILD), skin manifestations, and calcinosis. Anti-MDA5 antibodies, in particular, are linked to clinically amyopathic dermatomyositis and rapidly progressive ILD. These antibodies are important biomarkers for guiding clinical management and understanding disease pathogenesis.

Dermatomyositis-Specific Autoantibodies and Clinical Associations

  • Anti-Mi-2: Found in 10–21% of DM patients in the USA and Europe; associated with classic DM rash, good prognosis, high creatine kinase (CK), and nearly universal muscle involvement. Patients often experience relapses but generally have a favorable outcome[3].

  • Anti-MDA5 (also known as anti-CADM140): Prevalence varies by region (0–13% in USA/Europe, up to 37% in Asia). Strongly associated with clinically amyopathic dermatomyositis, rapidly progressive interstitial lung disease (ILD), arthritis, cutaneous ulcers, alopecia, and hyperferritinemia. This antibody is a highly specific serological marker and may play a pathogenic role through interferon-mediated vasculopathy[1]``[2]``[3].

  • Anti-TIF1γ (anti-155/140): Present in 8–41% of DM patients in Western countries and 7–14% in Japan. Closely linked to cancer-associated dermatomyositis in adults and severe skin manifestations such as poikiloderma and palatal patches. Also common in juvenile DM[2]``[3].

  • Anti-NXP-2 (anti-MJ): Found in 3–30% of DM patients in the West and 2–4% in Japan. Associated with calcinosis, malignancy, severe dysphagia, myalgia, distal weakness, and intestinal vasculopathy. Also prevalent in juvenile DM with a high incidence of calcinosis[2]``[3].

  • Anti-SAE (small ubiquitin-like modifier activating enzyme): Present in 5–10% of DM patients in the West and 2–3% in Asia. Characterized by dysphagia, an “angel wing” rash on the back, and skin-predominant disease that may precede myositis[3].

  • Anti-synthetase antibodies (e.g., anti-Jo-1, anti-PL-7, anti-PL-12): Though more typical of antisynthetase syndrome, which overlaps with DM features, these antibodies target aminoacyl-tRNA synthetases and are associated with myositis, ILD, arthritis, Raynaud’s phenomenon, and mechanic’s hands[2]``[3].

Pathogenesis and Clinical Implications

  • Anti-MDA5 antibodies target a cytosolic protein essential for antiviral immunity and are linked to a vasculopathic process mediated by interferons affecting skin and lung tissue[1].

  • The presence of MSAs correlates with distinct clinical phenotypes, aiding in disease classification and prognosis. For example, anti-TIF1γ and anti-NXP-2 antibodies are markers for cancer-associated DM, while anti-MDA5 indicates a risk for rapidly progressive ILD[2]``[3].

  • The pathogenic role of these antibodies remains under investigation, but their detection is crucial for early diagnosis and tailored treatment strategies[2].

Sources

  1. [1] Nombel A et al. Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol. 2021.
  2. [2] Understanding Myositis. Myositis Autoantibodies. 2025.
  3. [3] Hodgkinson LM et al. Dermatomyositis autoantibodies: how can we maximize their clinical utility? Front Immunol. 2019.
  1. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.773352/full
  2. https://understandingmyositis.org/myositis-antibody-testing/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8033377/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8990210/
  5. https://arupconsult.com/ati/dermatomyositis-autoantibody-panel

AI-generated answer based on the cited sources. Check the sources before applying it.

Have a question about your own case? Itaca answers with sources in seconds.

Ask a question